Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,928.00    -30.00 (-1.01%)
Bid:
2,930.00
Ask:
2,936.00
Spread: 6.00 (0.205%)
Market Cap: £1.62b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

16 Apr 2025 07:00

RNS Number : 1833F
Oxford Instruments PLC
16 April 2025
 

 

 

Oxford Instruments plc

Full-year trading update - 16 April 2025

 

Strong H2 delivered - full-year trading in line with expectations

Good progress on execution of the strategy

 

 

Oxford Instruments plc, a leading provider of scientific technology and expertise to academic and commercial partners, is today issuing a trading update for the year ended 31 March 2025.

 

We have delivered a strong full-year performance, in line with expectations. This has been underpinned by continued momentum in order intake and good progress on the execution of our strategy. We are seeing the benefits of the actions we have taken to drive operational excellence, improve commercial execution, and bring a greater focus on our costs.

 

Revenue growth in the second half has been strong, as anticipated, resulting in full-year revenue growth expected to be around +9% at constant currency1 (+6% at actual rates) versus the prior year. Demand has remained healthy, with 3% year-on-year order growth at constant currency.

 

Full-year adjusted operating profit2 is expected to be up around 13% on a constant currency basis (3% at actual rates), in line with market expectations. Group constant currency adjusted operating margin is expected to be around 17.8% (16.5% at actual rates), up 70 bps year on year with margin progress in both divisions.

 

Our Imaging & Analysis division, which represents two-thirds of Group revenue and around 90% of its operating profit, has performed well, growing both orders and revenue whilst maintaining its excellent operating margin above 24% at constant currency. Semiconductor revenues have grown strongly and, along with materials analysis, have offset continuing softness in the healthcare and life science end market.

 

Our Advanced Technologies division has delivered strong double digit constant currency revenue growth. As anticipated, we delivered a number of large customer orders in our quantum business which, together with operational improvements, resulted in a return to profitability. We have also continued to grow our compound semiconductor business in its new facility and increase our Tier 1 customer base, achieving both double-digit revenue growth and a margin improvement.

Richard Tyson, CEO, commented:

 "I am very pleased with how the team have embraced the strategy, delivering strong results despite the macro volatility seen in H2 and the execution of our pivot away from certain market segments in China."

"We continue to closely monitor and adapt to the potential impacts of macro events. Oxford Instruments' growth and resilience is underpinned by our diversified portfolio of market-leading technologies, deployed in multiple structurally growing sectors across all the major geographies. In addition, there are significant opportunities within our own control, as we accelerate our operational transformation programme, work to simplify and standardise our business, and drive a continued critical focus on product profitability."

Oxford Instruments management will present its full-year results to analysts and investors at Deutsche Numis, 45 Gresham Street, London EC2V 7BF, on 10 June 2025.

 

Notes:

1. Constant currency numbers are prepared on a month-by-month basis using the translational and transactional exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year. Transactional exchange rates include the effect of our hedging programme.

2. Adjusted items exclude the amortisation and impairment of acquired intangible assets, acquisition items, business reorganisation costs, other significant non‑recurring items, and the mark-to-market movement of financial derivatives.

 

The financial information in this trading update is unaudited.

LEI: 213800J364EZD6UCE231

 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Head of Investor Relations Stephen.lamacraft@oxinst.com 

 

MHP Group

Katie Hunt/Tim Rowntree/ 07710 117517

Veronica Farah oxfordinstruments@mhpgroup.com

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductors, and healthcare & life science. Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). For more information, visit www.oxinst.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKPBDFBKDPQD
Date   Source Headline
12th Mar 202011:11 amPRNDirector/PDMR Shareholding
4th Mar 202010:02 amPRNAppointment of External Auditor
2nd Mar 202012:06 pmPRNTotal Voting Rights
2nd Mar 202012:02 pmRNSPrice Monitoring Extension
27th Feb 202012:07 pmRNSSecond Price Monitoring Extn
27th Feb 202012:02 pmRNSPrice Monitoring Extension
24th Feb 20207:00 amRNSDisposal of OI Healthcare business in the US
10th Feb 20201:49 pmPRNDirector/PDMR Shareholding
3rd Feb 202012:41 pmPRNTotal Voting Rights
29th Jan 20207:00 amRNSSale of Minority Share in Scienta Omicron
23rd Jan 202010:52 amPRNAdditional Listing
13th Jan 20209:55 amPRNDirector/PDMR Shareholding
10th Jan 202012:02 pmRNSPrice Monitoring Extension
9th Jan 202010:42 amPRNTotal Voting Rights
9th Jan 20209:41 amPRNBlocklisting - Interim Review
3rd Jan 20208:36 amPRNHolding(s) in Company
11th Dec 20194:03 pmPRNDirector/PDMR Shareholding
2nd Dec 20192:54 pmPRNTotal Voting Rights
12th Nov 201912:49 pmPRNDirector/PDMR Shareholding
12th Nov 20197:00 amRNSHalf-year Report
11th Oct 201912:02 pmRNSPrice Monitoring Extension
10th Oct 20194:34 pmPRNDirector/PDMR Shareholding
3rd Oct 201911:00 amPRNTotal Voting Rights
11th Sep 20193:30 pmPRNDirector/PDMR Shareholding
11th Sep 201912:12 pmPRNResult of AGM
11th Sep 201910:50 amPRNDirector/PDMR Shareholding
10th Sep 20197:00 amRNSChairman's AGM Statement 2019
29th Aug 201912:07 pmRNSSecond Price Monitoring Extn
29th Aug 201912:02 pmRNSPrice Monitoring Extension
22nd Aug 20191:24 pmPRNHolding(s) in Company
13th Aug 201910:26 amPRNDirector/PDMR Shareholding
15th Jul 20194:26 pmPRNDirector/PDMR Shareholding
11th Jul 201911:49 amPRNDirector/PDMR Shareholding
1st Jul 201911:07 amPRNBlocklisting - Interim Review
27th Jun 20195:01 pmPRNHolding(s) in Company
26th Jun 20195:30 pmRNSRPC Group
11th Jun 20191:02 pmPRNDirector/PDMR Shareholding
11th Jun 20197:00 amRNSFinal Results
30th May 20191:18 pmPRNHolding(s) in Company
13th May 201910:27 amPRNDirector/PDMR Shareholding
11th Apr 201912:00 pmPRNDirector/PDMR Shareholding
11th Apr 20197:00 amRNSTrading Statement
22nd Mar 20197:00 amRNSContract win
11th Mar 20191:40 pmPRNDirector/PDMR Shareholding
12th Feb 20191:32 pmPRNDirector/PDMR Shareholding
1st Feb 20199:56 amPRNDirector Declaration
15th Jan 201910:28 amPRNAdditional Listing
14th Jan 20194:01 pmPRNBlocklisting - Interim Review
11th Jan 201910:28 amPRNDirector/PDMR Shareholding
3rd Jan 201912:26 pmPRNDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.